Cancer Family
Pancreaticobiliary Neoplasm
CI-CAN-00000309Explore in graph →
Non-malignant1,205 active trials11 approved drugs92 evidence items
- NCIt
- C223357
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000309Explore in graph →
Clinical trials
5,005 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01430052 | Chemoradiotherapy With Gemcitabine/S-1 vs Gemcitabine/S-1 for Locally Advanced Pancreatic Cancer | completed | Phase 2 | 110 | Osaka Medical Center for Cancer and Cardiovascular DiseasesOTHER | 1 | Nov 21, 2017 | clinicaltrials |
| NCT02862015 | Multicenter RCT of the Clinical Effectiveness of Oncothermia With Chemotherapy in Metastatic Pancreatic Cancer Patients(Oncothermia) | unknown | Phase 2 | 100 | Seoul National University HospitalOTHER |
| 1 |
| Oct 31, 2017 |
| clinicaltrials |
| NCT00383760 | Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients | completed | Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Oct 20, 2017 | clinicaltrials |
| NCT03316326 | S-1, Irinotecan, and Oxaliplatin in Locally-Advanced Pancreatic Cancer | unknown | Phase 2 | 35 | National Taiwan University HospitalOTHER | 0 | Oct 20, 2017 | clinicaltrials |
| NCT01320254 | PiCCA Study (Panitumumab in Combination With Cisplatin/Gemcitabine)(PiCCA) | completed | Phase 2 | 93 | Hannover Medical SchoolOTHER | 1 | Oct 12, 2017 | clinicaltrials |
| NCT00833859 | Neoadjuvant Gemcitabine, Docetaxel, and Capecitabine in Combination With Stereotactic Radiosurgery | terminated | Phase 2 | 2 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 9, 2017 | clinicaltrials |
| NCT01688336 | FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer | terminated | Phase 2 | 9 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Oct 6, 2017 | clinicaltrials |
| NCT02017015 | Safety and Efficacy Study of Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Metastatic Pancreatic Cancer(PANC-001) | completed | Phase 2 | 83 | CelgeneINDUSTRY | 1 | Sep 26, 2017 | clinicaltrials |
| NCT01971281 | Safety Feasibility and Effect of TTFields (150 kHz) Concomitant With Gemcitabine or Concomitant With Gemcitabine Plus Nab-paclitaxel for Front-line Therapy of Advanced Pancreatic Adenocarcinoma (PANOVA) | unknown | Phase 1 / Phase 2 | 40 | NovoCure Ltd.INDUSTRY | 2 | Sep 13, 2017 | clinicaltrials |
| NCT00033540 | S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma | completed | Phase 2 | 57 | SWOG Cancer Research NetworkNETWORK | 1 | Sep 12, 2017 | clinicaltrials |
| NCT02042443 | Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery(S1310) | completed | Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | Sep 12, 2017 | clinicaltrials |
| NCT03278015 | Phase 2 Trial of Gemcitabine vs S-1 vs Gemcitabine Plus Nab-paclitaxel as Adjuvant Chemotherapy of Post-operative Pancreatic Cancer Patients | unknown | Phase 2 | 90 | Chinese PLA General HospitalOTHER | 1 | Sep 11, 2017 | clinicaltrials |
| NCT01553019 | Postoperative Proton Radiotherapy With Chemo for Pancreatic Cancer(PC03) | completed | Phase 2 | 2 | University of FloridaOTHER | 1 | Sep 6, 2017 | clinicaltrials |
| NCT01150630 | Gemcitabine, Cisplatin, Epirubicin, and Capecitabine in Treating Patients With Stage I-II Resectable Pancreatic Cancer(PACT-15) | completed | Phase 2 | 98 | IRCCS San RaffaeleOTHER | 1 | Sep 1, 2017 | clinicaltrials |
| NCT01730222 | A Phase I-II Study of PAXG in Stage III-IV Pancreatic Adenocarcinoma(PACT-19) | completed | Phase 1 / Phase 2 | 137 | IRCCS San RaffaeleOTHER | 1 | Sep 1, 2017 | clinicaltrials |
| NCT01523457 | Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer(FOLFIRINOX) | completed | Phase 2 | 75 | Yale UniversityOTHER | 1 | Aug 30, 2017 | clinicaltrials |
| NCT01531712 | Study of Neoadjuvant Treatment in Patients With Pancreatic Cancer That is Potentially Resectable | terminated | Phase 2 | 6 | Institut Català d'OncologiaOTHER | 1 | Aug 29, 2017 | clinicaltrials |
| NCT03167112 | A Study of Administering FOLFIRINOX Before Surgery For Potentially Curable Pancreatic Cancer(Folfirinox) | unknown | Phase 2 | 20 | Petr KavanOTHER | 1 | Aug 29, 2017 | clinicaltrials |
| NCT01693419 | S-1, Gemcitabine and Erlotinib for Advanced Pancreatic Cancer | completed | Phase 2 | 37 | Hallym University Medical CenterOTHER | 1 | Aug 23, 2017 | clinicaltrials |
| NCT03251365 | Intrabdominal Hyperthermic Chemotherapy and Pancreatic Cancer | unknown | Phase 2 / Phase 3 | 42 | Hospital General de Ciudad RealOTHER | 1 | Aug 16, 2017 | clinicaltrials |
| NCT01195415 | Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer | completed | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Aug 7, 2017 | clinicaltrials |
| NCT01040000 | QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer | completed | Phase 1 / Phase 2 | 94 | Precision Biologics, IncINDUSTRY | 1 | Aug 4, 2017 | clinicaltrials |
| NCT00386516 | Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer | withdrawn | Phase 2 | 0 | Galectin Therapeutics Inc.INDUSTRY | 1 | Aug 1, 2017 | clinicaltrials |
| NCT01303029 | Safety and Efficacy Study of Gemcitabine-erlotinib Versus Gemcitabine-erlotinib-capecitabine in Patients With Metastatic Pancreatic Cancer(GECA) | completed | Phase 2 | 120 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)OTHER | 1 | Aug 1, 2017 | clinicaltrials |
| NCT02482454 | Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma | active not recruiting | Phase 2 / Phase 3 | 50 | The First People's Hospital of ChangzhouOTHER | 1 | Aug 1, 2017 | clinicaltrials |
| NCT02035072 | Phase II Study of Hypofractionated Radio-chemotherapy With Gemcitabine Plus Oxaliplatin for Unresectable Nonmetastatic Locally Advanced Pancreatic Cancer. | completed | Phase 2 | 40 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Jul 21, 2017 | clinicaltrials |
| NCT01729481 | Gemcitabine Plus Erlotinib in RASH-positive Patients With Metastatic Pancreatic Cancer(ML22774) | unknown | Phase 2 | 150 | Ludwig-Maximilians - University of MunichOTHER | 1 | Jul 19, 2017 | clinicaltrials |
| NCT02108782 | Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors | withdrawn | Phase 2 | 0 | Academic and Community Cancer Research UnitedOTHER | 0 | Jul 19, 2017 | clinicaltrials |
| NCT00609336 | Perioperative Therapy for Resectable Pancreatic Cancer | completed | Phase 2 | 35 | University of WashingtonOTHER | 1 | Jul 13, 2017 | clinicaltrials |
| NCT01016483 | Trial of Gemcitabine With or Without MSC1936369B in Pancreatic Cancer | completed | Phase 1 / Phase 2 | 141 | EMD SeronoINDUSTRY | 2 | Jul 13, 2017 | clinicaltrials |
| NCT00085410 | Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder | terminated | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT02117258 | Z-360 Plus GEM in Subjects With Metastatic Pancreatic Adenocarcinoma(ZIPANG) | completed | Phase 2 | 167 | Zeria PharmaceuticalINDUSTRY | 3 | Jul 2, 2017 | clinicaltrials |
| NCT03204019 | A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor | unknown | Phase 2 | 60 | Chinese Academy of Medical SciencesOTHER | 1 | Jun 29, 2017 | clinicaltrials |
| NCT01273805 | Hydroxychloroquine in Previously Treated Patients With Metastatic Pancreatic Cancer | completed | Phase 2 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 14, 2017 | clinicaltrials |
| NCT01515046 | Clinical Trial of High-dose Vitamin C for Advanced Pancreatic Cancer(PACMAN-II) | terminated | Phase 2 | 1 | Joseph J. CullenOTHER | 1 | Jun 8, 2017 | clinicaltrials |
| NCT00424827 | A Trial of Chemo & Radiation Therapy for Pancreatic Cancer | completed | Phase 2 | 11 | University of Massachusetts, WorcesterOTHER | 0 | Jun 1, 2017 | clinicaltrials |
| NCT00376987 | Zinc Supplements in Lowering Cadmium Levels in Smokers | completed | Phase 2 | 61 | Wake Forest University Health SciencesOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT00534001 | Bupropion in Helping Adults Stop Smoking | completed | Phase 2 | 95 | Roswell Park Cancer InstituteOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT01798147 | Selective Internal Radiotherapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Cholangiocellular Carcinoma (CCC). | unknown | Phase 2 | 24 | Johannes Gutenberg University MainzOTHER | 1 | May 23, 2017 | clinicaltrials |
| NCT00841035 | 7 Day's of Erlotinib Neo-adjuvant, Followed by Adjuvant Erlotinib-gemcitabine in Pancreatic Cancer Patients | terminated | Phase 2 | 6 | University of Alabama at BirminghamOTHER | 1 | May 19, 2017 | clinicaltrials |
| NCT01608711 | A Study of AGS-1C4D4 in Pancreatic Cancer Subjects Previously Treated in Protocol 2008002 | completed | Phase 2 | 2 | Agensys, Inc.INDUSTRY | 2 | May 16, 2017 | clinicaltrials |
| NCT01844817 | Phase II Trial Of Gemcitabine Plus Nab-Paclitaxel +/- OGX-427 In Patients With Metastatic Pancreatic Cancer(Rainier) | completed | Phase 2 | 132 | SCRI Development Innovations, LLCOTHER | 1 | May 16, 2017 | clinicaltrials |
| NCT02243007 | Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer | terminated | Phase 2 | 7 | Massachusetts General HospitalOTHER | 1 | May 16, 2017 | clinicaltrials |
| NCT00366457 | Gemcitabine, Bevacizumab and Erlotinib in Pancreatic Cancer | completed | Phase 2 | 32 | Massachusetts General HospitalOTHER | 1 | May 15, 2017 | clinicaltrials |
| NCT02202785 | A Study of MLN0264 in Patients With Pancreatic Cancer | terminated | Phase 2 | 43 | Millennium Pharmaceuticals, Inc.INDUSTRY | 4 | May 15, 2017 | clinicaltrials |
| NCT00691054 | Abraxane Therapy in Patients With Pancreatic Cancer Who Failed First-Line Gemcitabine Therapy | completed | Phase 2 | 20 | University of MiamiOTHER | 2 | May 11, 2017 | clinicaltrials |
| NCT00948688 | Vorinostat With XRT and 5-FU for Locally Advanced Adenocarcinoma of the Pancreas | terminated | Phase 1 / Phase 2 | 10 | Massachusetts General HospitalOTHER | 1 | May 10, 2017 | clinicaltrials |
| NCT01272791 | Trial of Gemcitabine With or Without Bavituximab in Patients With Previously Untreated Stage IV Pancreatic Cancer | completed | Phase 2 | 70 | Peregrine PharmaceuticalsINDUSTRY | 2 | Apr 19, 2017 | clinicaltrials |
| NCT00585078 | Capecitabine and Oxaliplatin in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma | completed | Phase 2 | 40 | Beth Israel Deaconess Medical CenterOTHER | 1 | Apr 10, 2017 | clinicaltrials |
| NCT00550836 | Erlotinib and Gemcitabine With or Without Panitumumab in Treating Patients With Metastatic Pancreatic Cancer | completed | Phase 2 | 104 | Alliance for Clinical Trials in OncologyOTHER | 1 | Apr 5, 2017 | clinicaltrials |
Data updated 24 days agoSource updated Nov 21, 2017source: clinicaltrials